AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 8th, 2018 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Matthew During (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its President and Chief Scientific Officer (“CSO”) pursuant to the terms of an Executive Employment Agreement with the Company dated June 5, 2015 (the “Prior Agreement”). Executive and the Company hereby agree to amend and restate the Prior Agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of the effective date of the first registration statement filed by the Company to register shares of its common stock for sale to the public through one or more underwriters (the “Effective Date”), and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain capitalized terms used in this Agreement are defined in Section 6.
